Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Epirium
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Epirium has advanced its first clinical candidate EPM-01 (Epicatechin) in Becker muscular dystrophy and plans to follow with drug development targeting other disorders associated with mitochondrial dysfunction and tissue degeneration.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
August 27, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Epirium
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy
Details : The Phase 1 open-label, dose-escalation study is evaluating the safety, preliminary clinical efficacy and potential biomarkers of three doses of EPM-01 in participants with Becker or Becker-like muscular dystrophy.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 12, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Muscular Dystrophy, Duchenne.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 13, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company's prior studies have shown that EB 002 can stimulate mitochondrial biogenesis, contributing to the restoration of tissue bioenergetics, thus upregulating key protein production.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 14, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable